15 July 2021AmericasMuireann Bolger
Novartis accused of owing $47m in IP royalties
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Biotechnology
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
Editor's picks
Editor's picks
Americas
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Biotechnology
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.
Americas
30 January 2020 Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.
Americas
3 April 2017 AbbVie has filed a declaratory judgment against Novartis, alleging that its patents covering the treatment of hepatitis C virus are invalid.
Biotechnology
26 July 2021 A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.